Blue Light Phototherapy Safe, Effective for Acne Vulgaris

This article originally appeared here.
Share this content:
Blue Light Phototherapy Safe, Effective for Acne Vulgaris
Blue Light Phototherapy Safe, Effective for Acne Vulgaris

THURSDAY, Sept. 8, 2016 (HealthDay News) -- The KLOX BioPhotonic System LED blue light device using specific photo-converter chromophores is safe and efficacious for acne vulgaris, according to a study published online Aug. 30 in the International Journal of Dermatology.

Christina Antoniou, M.D., from the University of Athens in Greece, and colleagues randomly selected one patient hemiface to receive six weeks of twice-weekly treatment with the LED light and the photo-converter chromophores, while the contralateral hemiface was not treated. All patients were provided with a skin cleanser and non-comedogenic cream with ultraviolet protection to be used on the entire face. Patients were followed for an additional six weeks after completion of the six-week treatment period.

The researchers found that 51.7 percent of the patients had a reduction of at least two grades in the Investigator's Global Assessment (IGA) scale at week 12. Patients with a baseline IGA grade of 3 and 4 had a success rate (grade drop of 2 or more) of 45.3 and 61.1 percent, respectively, at 12 weeks. These results were confirmed in acne inflammatory lesion counts, with a reduction of at least 40 percent in 81.6 percent of treatment hemifaces after 12 weeks. Treatment was safe and well tolerated, with no serious adverse events.

"The BioPhotonic System comprised of LED blue-light phototherapy and photo-converter chromophores was found to be efficacious and safe, with a sustained clinical response at 12 weeks," the authors write.

Two authors disclosed ties to KLOX Technologies, which funded the trial.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »